Federal Register Notice: FDA is referring Kemstro (baclofen) and Droxia (hydroxyurea) to the Foundation for the National Institutes of Health to conduct pediatric studies and is publishing this notice in accordance with the Best Pharmaceuticals for Children Act. To view this notice, click here.
